SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 27th, 2016 • Galectin Therapeutics Inc • Pharmaceutical preparations • Delaware
This Securities Purchase Agreement (this “Agreement”) is dated as of September 22, 2016, between Galectin Therapeutics, Inc., a Nevada corporation (the “Company”), and 10X Fund, L.P., a Delaware limited partnership (the “Purchaser”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • September 27th, 2016 • Galectin Therapeutics Inc • Pharmaceutical preparations • Delaware
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of September 22, 2016, by and among Galectin Therapeutics, Inc., a Nevada corporation (the “Issuer”), 10X Fund, L.P., a Delaware limited partnership, or its registered successors and assigns (the “Holder”).
LOCK-UP LETTER AGREEMENT September 22, 2016Lock-Up Letter Agreement • September 27th, 2016 • Galectin Therapeutics Inc • Pharmaceutical preparations
This Agreement contains restrictions related to the common stock (“Common Stock”) and preferred stock (“Preferred Stock”) of Galectin Therapeutics, Inc. (the “Company”). In consideration of the warrants described herein (the “Lock-Up Warrants”) to be issued by the Company to 10X Fund, L.P. (“10X Fund”) to purchase up to 1,000,000 shares of Common Stock and the Lock Up Warrant as described in the 2016 Securities Purchase Agreement (as hereinafter defined), and for other good and valuable consideration, 10X Fund hereby irrevocably agrees that, for a period commencing on the date hereof and ending on the eighteen (18) month anniversary of the date hereof (such 18 month period, the “Lock-Up Period”), without the prior written consent of the Company, 10X Fund will not, directly or indirectly, except as otherwise specified herein, (1) offer for sale, sell, contract to sell, pledge, or otherwise dispose of (or enter into any transaction or device that is designed to, or could be expected to,
